Across TCGA pan-cancer cohorts, MIR548AG1 RNA is linked to patient survival in 1 of 34 cancer types, making it the most broadly survival-associated MIR548AG1 data layer.
The strongest signal is observed in stomach adenocarcinoma (STAD), where higher MIR548AG1 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated MIR548AG1 expression acts as an unfavorable survival marker.
STAD are the cancer types where MIR548AG1 RNA most reproducibly stratifies survival.